Tunstall Healthcare

PHASE Scientific | June 22, 2020

PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The study presented by MD Anderson Cancer Center evaluates the efficacy of PHASE Scientific's liquid phase DNA isolation method (PHASIFY™) in improving cancer liquid biopsy sensitivity.Early-stage cancer diagnostics and cancer screening applications are limited ...

MEDTECH, AI

Quantum-Si | January 10, 2023

The leading Protein Sequencing Company™, Quantum-Si, recently announced that it signed a partnership and license agreement with Biovista to offer customers more significant proteomic insights beyond their protein sequence output. Biovista utilizes artificial intelligence in multiple formats to analyze enormous data repositories and visualize non-obvious networks and connections between proteins, diseases, and drug mechanisms of action. The partnership enhances Quantium-Si...

Micreos | September 22, 2020

Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis. The study marks the world's first evaluation of a pharmaceutical endolysin for topical use in humans. Endolysins are highly specific enzymes that cut the bacterial cell wall, rapidly killing only the target bacteria, regardl...

MEDTECH

Sequence Bio | April 08, 2022

Sequence Bio, a Newfoundland and Labrador-based discovery biology company, announced today that it has entered into a collaboration agreement with Danish dermatology specialists LEO Pharma, for use of Sequence Bio's proprietary discovery platform to identify novel dermatologic drug targets. Under the terms of the three year agreement, Sequence Bio will perform multi-omic analyses of samples from powered discovery cohorts across multiple dermatologic indications. LEO Pharma will leverage insi...